Analysis Of Income And Expense [Abstract]

Egetis Therapeutics - Filing #5995613

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
Analysis of income and expense [abstract]
Material income and expense [abstract]
Research and development expense
1,462,000,000 SEK
1,940,000,000 SEK
Finance income (cost)
138,000,000 SEK
20,000,000 SEK
Miscellaneous other operating expense
76,000,000 SEK
134,000,000 SEK
Sales and marketing expense
1,097,000,000 SEK
866,000,000 SEK
Gains (losses) on change in fair value of derivatives [abstract]
Gains (losses) on change in fair value of derivatives
45,000,000 SEK
27,000,000 SEK
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
- SEK
3,435,000,000 SEK
- SEK
- SEK
3,435,000,000 SEK
- SEK
- SEK
3,270,000,000 SEK
3,270,000,000 SEK
- SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.